Literature DB >> 33648520

Determining mutational burden and signature using RNA-seq from tumor-only samples.

Erik Jessen1, Yuanhang Liu2, Jaime Davila2, Jean-Pierre Kocher2, Chen Wang3.   

Abstract

BACKGROUND: Traditionally, mutational burden and mutational signatures have been assessed by tumor-normal pair DNA sequencing. The requirement of having both normal and tumor samples is not always feasible from a clinical perspective, and led us to investigate the efficacy of using RNA sequencing of only the tumor sample to determine the mutational burden and signatures, and subsequently molecular cause of the cancer. The potential advantages include reducing the cost of testing, and simultaneously providing information on the gene expression profile and gene fusions present in the tumor.
RESULTS: In this study, we devised supervised and unsupervised learning methods to determine mutational signatures from tumor RNA-seq data. As applications, we applied the methods to a training set of 587 TCGA uterine cancer RNA-seq samples, and examined in an independent testing set of 521 TCGA colorectal cancer RNA-seq samples. Both diseases are known associated with microsatellite instable high (MSI-H) and driver defects in DNA polymerase ɛ (POLɛ). From RNA-seq called variants, we found majority (> 95%) are likely germline variants, leading to C > T enriched germline variants (dbSNP) widely applicable in tumor and normal RNA-seq samples. We found significant associations between RNA-derived mutational burdens and MSI/POLɛ status, and insignificant relationship between RNA-seq total coverage and derived mutational burdens. Additionally we found that over 80% of variants could be explained by using the COSMIC mutational signature-5, -6 and -10, which are implicated in natural aging, MSI-H, and POLɛ, respectively. For classifying tumor type, within UCEC we achieved a recall of 0.56 and 0.78, and specificity of 0.66 and 0.99 for MSI and POLɛ respectively. By applying learnt RNA signatures from UCEC to COAD, we were able to improve our classification of both MSI and POLɛ.
CONCLUSIONS: Taken together, our work provides a novel method to detect RNA-seq derived mutational signatures with effective procedures to remove likely germline variants. It can leads to accurate classification of underlying driving mechanisms of DNA damage deficiency.

Entities:  

Keywords:  COAD; Cancer; Mutational burden; Mutational signatures; RNA-seq; UCEC

Year:  2021        PMID: 33648520      PMCID: PMC7923324          DOI: 10.1186/s12920-021-00898-y

Source DB:  PubMed          Journal:  BMC Med Genomics        ISSN: 1755-8794            Impact factor:   3.063


  14 in total

Review 1.  Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.

Authors:  Christian Blank; Thomas F Gajewski; Andreas Mackensen
Journal:  Cancer Immunol Immunother       Date:  2004-12-15       Impact factor: 6.968

2.  REDIportal: a comprehensive database of A-to-I RNA editing events in humans.

Authors:  Ernesto Picardi; Anna Maria D'Erchia; Claudio Lo Giudice; Graziano Pesole
Journal:  Nucleic Acids Res       Date:  2016-09-01       Impact factor: 16.971

3.  Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR.

Authors:  Nirosha Suraweera; Alex Duval; Maryline Reperant; Christelle Vaury; Daniela Furlan; Karen Leroy; Raquel Seruca; Barry Iacopetta; Richard Hamelin
Journal:  Gastroenterology       Date:  2002-12       Impact factor: 22.682

4.  PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells.

Authors:  Christian Blank; Ian Brown; Amy C Peterson; Mike Spiotto; Yoshiko Iwai; Tasuku Honjo; Thomas F Gajewski
Journal:  Cancer Res       Date:  2004-02-01       Impact factor: 12.701

5.  Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels.

Authors:  Zsofia K Stadler; Francesca Battaglin; Sumit Middha; Jaclyn F Hechtman; Christina Tran; Andrea Cercek; Rona Yaeger; Neil H Segal; Anna M Varghese; Diane L Reidy-Lagunes; Nancy E Kemeny; Erin E Salo-Mullen; Asad Ashraf; Martin R Weiser; Julio Garcia-Aguilar; Mark E Robson; Kenneth Offit; Maria E Arcila; Michael F Berger; Jinru Shia; David B Solit; Leonard B Saltz
Journal:  J Clin Oncol       Date:  2016-03-28       Impact factor: 44.544

6.  PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients.

Authors:  A D'Incecco; M Andreozzi; V Ludovini; E Rossi; A Capodanno; L Landi; C Tibaldi; G Minuti; J Salvini; E Coppi; A Chella; G Fontanini; M E Filice; L Tornillo; R M Incensati; S Sani; L Crinò; L Terracciano; F Cappuzzo
Journal:  Br J Cancer       Date:  2014-10-28       Impact factor: 7.640

7.  RVboost: RNA-seq variants prioritization using a boosting method.

Authors:  Chen Wang; Jaime I Davila; Saurabh Baheti; Aditya V Bhagwate; Xue Wang; Jean-Pierre A Kocher; Susan L Slager; Andrew L Feldman; Anne J Novak; James R Cerhan; E Aubrey Thompson; Yan W Asmann
Journal:  Bioinformatics       Date:  2014-08-27       Impact factor: 6.937

8.  Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.

Authors:  Zachary R Chalmers; Caitlin F Connelly; David Fabrizio; Laurie Gay; Siraj M Ali; Riley Ennis; Alexa Schrock; Brittany Campbell; Adam Shlien; Juliann Chmielecki; Franklin Huang; Yuting He; James Sun; Uri Tabori; Mark Kennedy; Daniel S Lieber; Steven Roels; Jared White; Geoffrey A Otto; Jeffrey S Ross; Levi Garraway; Vincent A Miller; Phillip J Stephens; Garrett M Frampton
Journal:  Genome Med       Date:  2017-04-19       Impact factor: 11.117

9.  Patterns and processes of somatic mutations in nine major cancers.

Authors:  Peilin Jia; William Pao; Zhongming Zhao
Journal:  BMC Med Genomics       Date:  2014-02-19       Impact factor: 3.063

10.  MutationalPatterns: comprehensive genome-wide analysis of mutational processes.

Authors:  Francis Blokzijl; Roel Janssen; Ruben van Boxtel; Edwin Cuppen
Journal:  Genome Med       Date:  2018-04-25       Impact factor: 11.117

View more
  2 in total

1.  Estimating tumor mutational burden from RNA-sequencing without a matched-normal sample.

Authors:  Rotem Katzir; Noam Rudberg; Keren Yizhak
Journal:  Nat Commun       Date:  2022-06-02       Impact factor: 17.694

2.  Frequent POLE-driven hypermutation in ovarian endometrioid cancer revealed by mutational signatures in RNA sequencing.

Authors:  Jaime I Davila; Pritha Chanana; Vivekananda Sarangi; Zachary C Fogarty; S John Weroha; Ruifeng Guo; Ellen L Goode; Yajue Huang; Chen Wang
Journal:  BMC Med Genomics       Date:  2021-06-22       Impact factor: 3.063

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.